Chimeric Antigen Receptor Therapy

Carl H. June; Michel Sadelain · 2018 · New England Journal of Medicine

Paper

Abstract

Interview with Dr. Carl June on chimeric antigen receptor therapy. (09:04)Download This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors. Toxic effects of chimeric antigen receptor therapies include cytokine release syndrome and neurologic dysfunction.

Analysis

Paper intelligence

Summary

This interview with Dr. Carl June discusses chimeric antigen receptor (CAR) therapy, focusing on T-cell engineering for durable remissions in refractory tumors and highlighting toxicities like cytokine release syndrome and neurologic dysfunction.

Key findings

CAR therapy aims for durable remissions in treatment-refractory tumors.
Toxic effects include cytokine release syndrome.
Toxic effects include neurologic dysfunction.

Methods

T-cell engineering
Synthetic immunity

Limitations

Toxic effects of CAR therapies.
Cytokine release syndrome.
Neurologic dysfunction.

Applications

Treatment of treatment-refractory tumors.

Confidence100%

Discovery

Related papers

2023OpenAlex405 citations

TCR-engineered T cell therapy in solid tumors: State of the art and perspectives

Estelle Baulu; Célia Gardet; Nicolas Chuvin; Stéphane Depil

Feb 15, 2023Science Advances

2022OpenAlex224 citations

CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome

Silvia Arcangeli; Camilla Bove; Claudia Mezzanotte; Barbara Camisa; Laura Falcone; Francesco Manfredi; Eugenia Bezzecchi; Rita El Khoury; Rossana Norata; Francesca Sanvito; Maurilio Ponzoni; Beatrice Greco; Marta Angiola Moresco; Matteo G. Carrabba; Fabio Ciceri; Chiara Bonini; Attilio Bondanza; Monica Casucci

May 3, 2022Journal of Clinical Investigation

2021OpenAlex2,825 citations

CAR-T cell therapy: current limitations and potential strategies

Robert C. Sterner; Rosalie M. Sterner; Rosalie M. Sterner; Rosalie M. Sterner

Apr 6, 2021Blood Cancer Journal

2021OpenAlex273 citations

Promises and challenges of adoptive T-cell therapies for solid tumours

Matteo Morotti; Ashwag Albukhari; Abdulkhaliq Alsaadi; Mara Artibani; James D. Brenton; Stuart M. Curbishley; Tao Dong; Michael L. Dustin; Zhiyuan Hu; Nicholas McGranahan; Martin L. Miller; Laura Santana-Gonzalez; Leonard W. Seymour; Tingyan Shi; Peter Van Loo; Christopher Yau; Helen White; Nina Wietek; David N. Church; David C. Wedge; Ahmed A. Ahmed

Mar 29, 2021British Journal of Cancer

2021OpenAlex282 citations

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Yongxian Hu; Yali Zhou; Mingming Zhang; Wengang Ge; Yi Li; Li Yang; Guoqing Wei; Lu Han; Hao Wang; Shuhui Yu; Yi Chen; Yanbin Wang; Xiaohong He; Xingwang Zhang; Ming Gao; Jingjing Yang; Xiuju Li; Jiangtao Ren; He Huang

Feb 24, 2021Clinical Cancer Research

2020Crossref700 citations

TIGIT in cancer immunotherapy

Joe-Marc Chauvin; Hassane M Zarour

Sep 1, 2020Journal for ImmunoTherapy of Cancer

Source record

Publication metadata

Authors: Carl H. June; Michel Sadelain
Published: Jul 4, 2018
Journal or venue: New England Journal of Medicine
DOI: 10.1056/nejmra1706169
Paper type: journal article
Source: Openalex

DOI OpenAlex